Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone

Clinical Cancer Research

Volumn 6, Issue 5, 2000, Pages 1891-1895

  Drobnjak, Marija ^a   Osman, Iman ^a   Scher, Howard I ^a   Fazzari, Melissa ^a   Cordon Cardo, Carlos ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BONE METASTASIS; CARCINOGENESIS; CELL CYCLE G1 PHASE; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR GROWTH;

COHORT STUDIES; CYCLIN D1; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0034084926     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Lite, K. R., Srougi, M., Nesralhah, L. J., and Camara-Lopes, L. H. Analysis of p53 expression and proliferative assessment using PCNA in localized prostate carcinoma. Braz. J. Med. Biol. Res., 32: 283-288, 1999.
2. Moul, J. W. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy. Eur. Urol., 35: 399-407, 1999.
3. Matsushima, H., Goto, T., Hosaka, Y., Kitamura, T., and Kawabe, K. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation. Cancer (Phila.), 85: 1822-1827, 1999.
4. Imbriaco, M., Larson, S. M., Yeung, H. W., Mawlawi, O. R., Erdi, Y., Venkatraman, E. S., and Scher, H. I. A new parameter for measuring metastatic bone involvement by prostate cancer: the bone scan index. Clin. Cancer Res., 4: 1765-1772, 1998.
5. Chen, Y., Martinez, L. A., LaCava, M., Coghlan, L., and Conti, C. J. Increased cell growth and tumorigenicity in human prostate LNCaP cells by overexpression to cyclin Dl. Oncogene, 16: 1913-1920, 1998.
6. Agus, D., Cordon-Cardo, C., Fox, W., Drobnjak, M., Koff, A., Golde, D., and Scher, H. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J. Natl. Cancer Inst., 91: 1869-1876, 1999.
7. Gumbiner, L. M., Gumerlock, P. H., Mack, P. C., Chi, S. G., DeVere White, R. W., Mohler, J. L., Pretlow, T. G., and Tricoli, J. V. Overexpression of cyclin D1 is rare in human prostate carcinoma. Prostate, 38: 40-45, 1999.
8. Kallakury, B. V., Sheehan, C. E., Ambros, R. A., Fisher, H. A., Kaufman, R. P., Jr., and Ross, J. S. The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma. Cancer (Phila.), 80: 753-763, 1997.
9. Bubendorf, L., Kononen, J., Koivisto, P., Schraml, P., Moch, H., Gasser, T. C., Willi, N., Mihatsch, M. J., Sauter, G., and Kallioniemi, O. P. Survey of gene amplifications during prostate cancer progression by high-throughput fluorescence in situ hybridization on tissue microarrays. Cancer Res., 59: 803-806, 1999.
10. Caputi, M., Groeger, A. M., Esposito, V., Dean, C., De Luca, A., Pacilio, C., Muller, M. R., Giordano, G. G., Baldi, F., Wolner, E., and Giordano, C. A Prognostic role of cyclin D1 in lung cancer. Relationship to proliferating cell nuclear antigen. Am. J. Respir. Cell Mol. Biol., 20: 746-750, 1999.
11. Kim, S. H., Lewis, J. J., Brennan, M. F., Woodruff, J. M., Dudas, M., and Cordon-Cardo, C. Overexpression of cyclin D1 is associated with poor prognosis in extremity soft-tissue sarcomas. Clin. Cancer Res., 4: 2377-2382, 1998.
12. Osman, I., Scher, H., Zhang, Z-F., Soos, T. J., Hamza, R., Eissa, S., Khaled, H., Koff, A., and Cordon-Cardo, C. Expression of cyclin D1, but not cyclins E and A, is related to progression in bilharzial bladder cancer. Clin. Cancer Res., 3: 2247-2251, 1997.
13. Metha, C. R., and Patel, N. R. A network algorithm for performing Fisher's exact test in rXc contingency tables. J. Am. Stat. Assoc., 78: 427-434, 1983.
14. SAS/STAT User Guide, Version 6. Cary, NC: SAS Institute, Inc., 1990.
15. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observation. J. Am. Stat. Assoc., 53: 457-481, 1958.
16. Cordon-Cardo, C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am. J. Pathol., 147: 545-560, 1995.
17. Reissmann, P. T., Koga, H., Figlin, R. A., Holmes, E. C., and Slamon, D. J. Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small cell lung cancer. Lung Cancer Study Group. J. Cancer Res. Clin. Oncol., 125: 61-70, 1999.
18. Zhu, X. L., Hartwick, W., Rohan, T., and Kandel, R. Cyclin D1 gene amplification and protein expression in benign breast disease and breast carcinoma. Mod. Pathol., 11: 1082-1088, 1998.
19. Oyama, T., Kashiwabara, K., Yoshimoto, K., Arnold, A., and Koerner, F. Frequent overexpression of the cyclin D1 oncogene in invasive lobular carcinoma of the breast. Cancer Res., 58: 2876-2880, 1998.
20. Shiraishi, T., Watanabe, M., Muneyuki, T., Nakayama, T., Monta, J., Ito, H., Kotake, T., and Yatani, A. Clinicopathological study of p53, p21 (WAF1/CIP1) and cyclin D1 expression in human prostate cancers. Urol. Int., 61: 90-94, 1998.
21. Festuccia, C., Teti, A., Bianco, P., Guerra, F., Vicentini, C., Tennina, R., Villanova, I., Sciortino, G., and Bologna, M. Human prostatic tumor cells in culture produce growth and differentiation factors active on osteoblasts: a new biological and clinical parameter for prostatic carcinoma. Oncol. Res., 9: 419-431, 1997.
22. Hall, F. L., Williams, R. T., Wu, L., Wu, F., Carbonaro-Hall, D. A., Harper, J. W., and Warburton, D. Two potentially oncogenic cyclins, cyclin A and cyclin Dl, share common properties of subunit configuration, tyrosine phosphorylation and physical association with the Rb protein. Oncogene, 8: 1377-1384, 1993.
23. Sunters, A., McCluskey, J., and Grigoriadis, A. E. Control of cell cycle gene expression in bone development and during c-Fos-induced osteosarcoma formation. Dev. Genet., 22: 386-397, 1998.
24. Aguilera, N. S., Uusafr, M., Wenig, B. M., and Abbondanzo, S. L. J. The blastic variant of mantle cell lymphoma arising in Waldeyer's tonsillar ring. Laryngo. Rhinol. Otol., 112: 991-994, 1998.
25. Chhieng, C., Cranor, M., Lesser, M. E., and Rosen, P. P. Metaplastic carcinoma of the breast with osteocartilaginous heterologous elements. Am. J. Surg. Pathol., 22: 188-194, 1998.
26. Lai, R., Medeiros. L. J., Wilson, C. S., Sun, N. C., Koo, C., McCourty, A., and Brynes, R. K. Expression of the cell-cycle-related proteins E2F-1, p53, mdm-2, p21waf1, and Ki-67 in multiple myeloma: correlation with cyclin-D1 immunoreactivity. Mod. Pathol., 11: 642-647, 1998.
27. Agus, D. B., Golde, D. W., Sgouros, G., Ballangrud, A., Cordon-Cardo, C., and Scher, H. I. Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal. Cancer Res., 58: 3009-3014, 1998.
28. Macappilac, H., Humm, J., Akhurst, T., Osman, I., Scher, H., Pentlow, K., Shangde, C., Yeung, H., Squire, O., Finn, R., and Larson, S. Differential metabolism and pharmacokinetics of C-11 methionine and F-18 fluorodeoxyglucose (FDG) in androgen independent prostate cancer. J. Nucl. Med., in press, 2000.
29. Nupponen, N., and Visakorpi, T. Molecular biology of progression of prostate cancer. Eur. Urol., 35: 351-354, 1999.
30. McMahon, C., Suthiphongchai, T., DiRenzo, J., and Ewen, M. E. P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor. Proc. Natl. Acad. Sci. USA, 96: 5382-5387, 1999.